Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer.
Publication/Presentation Date
4-7-2023
Abstract
Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-resistant disease have significantly lower response rates to additional chemotherapy, with estimates as low as 10%-25%. We hypothesize that in patients with platinum-resistant ovarian cancer, treatment with immunotherapy followed by cytotoxic chemotherapy with antiangiogenic therapy results in prolonged survival without compromising quality of life. Our experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy resulted in progression-free survival durations significantly above previously published averages. Further studies evaluating the role of immunotherapy followed by chemotherapy in combination with drugs targeting angiogenesis are needed and may provide a long-sought after breakthrough for advancing survival in platinum-resistant ovarian cancer.
ISSN
1549-490X
Published In/Presented At
Kinney, R. E., Nair, S., Kim, C. H., Thomas, M. B., & DelaTorre, M. (2023). Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer. The oncologist, oyad079. Advance online publication. https://doi.org/10.1093/oncolo/oyad079
Disciplines
Medicine and Health Sciences
PubMedID
37027520
Department(s)
Department of Medicine, Hematology-Medical Oncology Division Fellows and Residents, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article